Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015

Date: December 23, 2015
Pages: 498
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A55886D8500EN
Leaflet:

Download PDF Leaflet

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015’, provides an overview of the Amyotrophic Lateral Sclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Amyotrophic Lateral Sclerosis Overview
Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies
Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes
Amyotrophic Lateral Sclerosis - Pipeline Products Glance
Amyotrophic Lateral Sclerosis - Products under Development by Companies
Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Drug Profiles
Amyotrophic Lateral Sclerosis - Recent Pipeline Updates
Amyotrophic Lateral Sclerosis - Dormant Projects
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2015
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Apotex, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen,Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Biogen, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Limited, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex S.A., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Grifols, S.A., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by IntelliCell BioSciences Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica Plc, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed S.L., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by UCB S.A., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by uniQure N.V., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Varinel, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics, Inc., H2 2015
Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H2 2015
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H2 2015
Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2015
Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2015
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

2-BBB Medicines BV
AB Science SA
Aestus Therapeutics, Inc.
Anavex Life Sciences Corp.
Angion Biomedica Corp.
Apodemus AB
Apogenix GmbH
Apotex, Inc.
ArmaGen,Inc.
BioCrea GmbH
Biogen, Inc.
BrainStorm Cell Therapeutics Inc.
CalAsia Pharmaceuticals, Inc.
Calico LLC
Catabasis Pharmaceuticals, Inc.
Cellceutix Corporation
Chronos Therapeutics Limited
Cytokinetics, Inc.
Daval International Limited
Edison Pharmaceuticals, Inc.
Eisai Co., Ltd.
Evotec AG
F. Hoffmann-La Roche Ltd.
Genervon Biopharmaceuticals, LLC
GeNeuro SA
GenKyoTex S.A.
GlaxoSmithKline Plc
Glialogix, Inc.
Grifols, S.A.
Herantis Pharma Plc
ImStar Therapeutics Inc.
IntelliCell BioSciences Inc.
Isis Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Kadimastem Ltd.
Karyopharm Therapeutics, Inc.
KineMed, Inc.
Kringle Pharma, Inc.
Kyorin Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Lascco SA
Lead Discovery Center GmbH
Maas Biolab
Mallinckrodt Plc
miCure Therapeutics Ltd.
miRagen Therapeutics, Inc.
MitoDys Therapeutics Limited
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neuraltus Pharmaceuticals, Inc.
Neurimmune Holding AG
Neurodyn Inc.
Neurotec Pharma SL
Neurotune AG
Nexgenix Pharmaceuticals, LLC
Orion Oyj
Orphazyme ApS
Oxford BioMedica Plc
Pharnext SAS
Primary Peptides, Inc.
ProMIS Neurosciences Inc.
Q Therapeutics, Inc.
ReceptoPharm, Inc.
Regenesance BV
reMYND NV
RhinoCyte, Inc.
RXi Pharmaceuticals Corporation
Saneron CCEL Therapeutics, Inc.
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
Spherium Biomed S.L.
Teva Pharmaceutical Industries Limited
Treeway BV
UCB S.A.
uniQure N.V.
Valeant Pharmaceuticals International, Inc.
Varinel, Inc.
ViroMed Co., Ltd.
Voyager Therapeutics, Inc.
Yooyoung Pharmaceutical Co., Ltd.
Skip to top


Ask Your Question

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: